EUVIMEDEUVIMED entdecken
Übersichtsarbeit

New Modalities and Carcinogenicity Assessment

Emily K Meseck iD, Paul Batty iD, Tae-Won Kim iD, Anne-Marie Mølck, Vivi Flou Hjorth Jensen, James Sidaway iD, Ronnie Chamanza iD, Charlotte Maria Dalsgaard, Dirk Schaudien iD, Sandra De Jonghe iD, Barbara Lenz iD, Thomas Nolte iD

Toxicologic Pathology · 2026-07 · 54 (5) · 370-373

DOI: 10.1177/01926233261453045 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Toxicologic Pathology, online erschienen am 23.06.2026. Verfasst von Emily K Meseck und 11 weiteren Autor:innen. Beteiligte Einrichtung: Novartis Pharmaceuticals Inc, East Hanover, New Jersey, USA. Hauptthemen laut MEDLINE: Carcinogenicity Tests, Drug Development. Die Arbeit nennt 7 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Emerging modalities in drug development including adeno-associated virus (AAV) and other viral-mediated gene therapy, targeted protein degraders, oligonucleotide, and chimeric antigen receptor-T cell (CAR-T) therapies require updated approaches in strategy and context for meaningful human carcinogenicity risk assessment. This may involve, but is not be limited to, traditional genetic toxicology and rodent bioassays. Speakers provided unique perspectives on these topics as well as an applicable and real-world case study that interrogated whether rat mammary gland cell proliferation was a useful tool with which to evaluate the carcinogenic potential of exogenous insulin.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinogenicity TestsDrug DevelopmentAnimalsFemaleHumansRatsGenetic TherapyRisk Assessment

Stichwörter der Autor:innen

carcinogenicity assessmentcell and gene therapynonclinical safetytargeted protein degraders

Autor:innen und Institutionen

  • Novartis Pharmaceuticals Inc, East Hanover, New Jersey, USA.
  • University College London, London, UK.
  • Ionis Pharmaceuticals, Carlsbad, California, USA.
  • Novo Nordisk A/S, Maaloev, Denmark.
  • ApconiX, Alderley Edge, UK.
  • Johnson & Johnson Innovative Medicine, High Wycombe, UK.

ORCID-Profile: Emily K Meseck, Paul Batty, Tae-Won Kim, James Sidaway, Ronnie Chamanza, Dirk Schaudien, Sandra De Jonghe, Barbara Lenz, Thomas Nolte

Zitieren

APA

Meseck, E. K., Batty, P., Kim, T. W., Mølck, A. M., Jensen, V. F. H., Sidaway, J., Chamanza, R., Dalsgaard, C. M., Schaudien, D., De Jonghe, S., Lenz, B., & Nolte, T. (2026). New Modalities and Carcinogenicity Assessment. Toxicologic Pathology, 54(5), 370-373. https://doi.org/10.1177/01926233261453045

Vancouver

Meseck EK, Batty P, Kim TW, Mølck AM, Jensen VFH, Sidaway J, et al. New Modalities and Carcinogenicity Assessment. Toxicologic Pathology. 2026;54(5):370-373. doi:10.1177/01926233261453045

BibTeX
@article{Meseck2026,
  author = {Meseck, Emily K and Batty, Paul and Kim, Tae-Won and Mølck, Anne-Marie and Jensen, Vivi Flou Hjorth and Sidaway, James and Chamanza, Ronnie and Dalsgaard, Charlotte Maria and Schaudien, Dirk and De Jonghe, Sandra and Lenz, Barbara and Nolte, Thomas},
  title = {New Modalities and Carcinogenicity Assessment},
  journal = {Toxicologic Pathology},
  year = {2026},
  volume = {54},
  number = {5},
  pages = {370--373},
  doi = {10.1177/01926233261453045}
}
Kostenlos starten →